|
Search of: "Amyloidosis" - List Results - ClinicalTrials.gov
Secondary (AA) Amyloidosis; Rheumatoid Arthritis; Nephrotic Syndrome; Familial Mediterranean Syndrome; Kidney Diseases; Gastrointestinal Diseases
Amyloidosis and Kidney Disease
The NIDDK's Division of Kidney, Urologic, and Hematologic Diseases supports basic research into normal kidney function and the diseases that impair normal function at the cellular and molecular levels, including Amyloidosis. Recently, NIDDK-sponsored researchers have identified several genes that may contribute to a hereditary form of primary Amyloidosis. In 2001, a team of researchers at the Indiana University School of Medicine located a mutation in the apolipoprotein A-II gene of a patient with kidney damage caused by Amyloidosis. The researchers noted that the patient had reabsorbed most of the amyloid. They theorize that learning how this reabsorption occurs may point the way to possible therapies for all forms of Amyloidosis. The NIDDK is also supporting multiple efforts to develop a blood detoxification system that will eliminate beta-2-microglobulin.
MedlinePlus
Medical Encyclopedia: Cardiac amyloidosis
Secondary Amyloidosis, also called AA type, rarely affects the heart. However, a subtype of secondary Amyloidosis, called senile Amyloidosis, involves the heart and blood vessels. Senile Amyloidosis is caused by overproduction of a protein different from both the AA and AL types. Senile cardiac Amyloidosis is becoming more common as the average age of the population increases.
Transthyretin Amyloidosis -- GeneReviews -- NCBI Bookshelf
It has been demonstrated that all disease-associated TTR variants are energetically (thermodynamically and kinetically) less stable than wild-type TTR. On the other hand, suppressor mutations (T119M and R104H) are more stable than wild-type TTR. In vitro amyloidogenicity correlates very well with protein stability. However extremely destabilized (highly amyloidogenic in vitro) TTR variants do not induce severe systemic Amyloidosis because serum concentrations of these TTR variants are very low. The low serum concentration of highly destabilized TTR variants is a result of degradation by endoplasmic reticulum (ER) quality control system (ERAD) of the hepatic cells. The most pathogenic TTR variant (L55P) exhibiting the earliest disease onset is the most destabilized variant that can be secreted at levels comparable to the wild type, barely avoiding ERAD. TTR variants that predominantly induce CNS Amyloidosis are the least stable variants. The choroid plexus secretes highly destabilized TTR variants more efficiently than hepatic cells, thus, it is thought, accounting for CNS selective amyloid deposition [ Sekijima et al 2003 , Hammarstr m et al 2003 , Mitsuhashi et al 2005 , Sekijima et al 2005 ]
Definition of amyloidosis - NCI Dictionary of Cancer Terms
A group of diseases in which protein is deposited in specific organs (localized Amyloidosis) or throughout the body (systemic Amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary Amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary Amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.
Dictionary of Cancer Terms
Dictionary of Cancer Terms
NGC - Search Results
Guidelines on the diagnosis and management of AL Amyloidosis.
Search of: myeloma - List Results - ClinicalTrials.gov
Search of: myeloma - List Results - ClinicalTrials.gov
MedlinePlus
Medical Encyclopedia: Primary amyloidosis
If you know you have primary Amyloidosis, call your health care provider if difficulty breathing, persistent swelling of the ankles or other areas, decreased urine output, or other symptoms occur. This may indicate that complications have developed.
healthfinder.gov — Amyloidosis Support Network, Inc. - ASN
In 2004, the Amyloidosis Support Network (ASN) began operations as a non-profit organization incorporated in the State of Georgia, USA. The Amyloidosis Support Network Inc. is organized exclusively for charitable purposes under Section 501(c)(3) of the Internal Revenue Code. The Amyloidosis Support Network, Inc. refers to our commitment to making a difference in the lives of patients and families. The Amyloidosis Support Network is committed to improving the survivability and quality of life of patients. Our core mission embodies two critical functions; high-value research programs and medical community awareness. In addition, we are committed to supporting patient education & advocacy programs.
Amyloidosis - Glossary Entry - Genetics Home Reference
A group of diseases in which protein is deposited in specific organs (localized Amyloidosis) or throughout the body (systemic Amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary Amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary Amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.
healthfinder.gov - Amyloidosis
This site provides answers to patients and their families about Amyloidosis -- a rare, bone marrow disease in which the heart, kidneys, nervous system and gastro-intestinal tract are most often affect ... Details >
Amyloidosis
ClinicalTrials.gov lists trials that are studying or have studied Amyloidosis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
Primary Systemic Amyloidosis
Primary Systemic Amyloidosis
Amyloidosis: Complications and Treatment
Amyloidosis: Complications and Treatment
FloridaHealthFinder.gov | Health Encyclopedia | Primary amyloidosis
If you know you have primary Amyloidosis, call your health care provider if difficulty breathing, persistent swelling of the ankles or other areas, decreased urine output, or other symptoms occur. This may indicate that complications have developed.
Guidelines on the diagnosis and management of AL amyloidosis.
Working Group Members : Jenny Bird, Avon Haematology Unit, Bristol Haematology and Oncology Centre, Bristol; Jamie Cavenagh, St Bartholomew's and The Royal London School of Medicine and Dentistry, Royal Free Hospital, London; Philip Hawkins, National Amyloidosis Centre, Royal Free Hospital, London; Helen Lachmann, National Amyloidosis Centre, Royal Free Hospital, London; Atul Mehta, Royal Free Hospital, London; and Diana Samson, Imperial College, London ( Chairman, UK Myeloma Forum ).
Energy Citations Database (ECD) - - Document #6915988
A study has been performed to evaluate the efficacy of gallium imaging in the detection of renal Amyloidosis.^Ten of the 11 patients who had biopsy-proven renal Amyloidosis demonstrated marked uptake in both kidneys.^One patient revealed moderate gallium uptake in his kidneys.^None of the patients had underlying renal or extrarenal pathology other than Amyloidosis, which could account for renal gallium uptake (renal infection, neoplasm, hepatic failure or frequent blood transfusions).^Four patients also had extrarenal foci of abnormal gallium uptake, suggesting other sites of amyloid deposits.^Our data strongly suggest that gallium imaging has a high sensitivity for detection of renal Amyloidosis.^Its specificity is enhanced significantly by careful review of the clinical history to exclude other known causes of renal gallium uptake.^Potentially, gallium imaging may be used to monitor the progress of patients under experimental therapy.
Guidelines on the diagnosis and management of AL amyloidosis.
At the end of a consultation, it is recommended that patients and their family/ carers are given written material which provides information on the condition. It should also guide patients and their family/ carers on access to information services. IMF (UK) and the Leukaemia Research Fund produce useful, patient-orientated booklets on the condition and its treatment. Written information is also available from the National Amyloidosis
Rare Diseases Terms - Office of Rare Diseases
Rare Diseases Terms - Office of Rare Diseases
|